[ad_1]
Newark, New Castle, USA, May 09, 2023 (GLOBE NEWSWIRE) — Growth Plus Reports estimated the size of the global market for anti-GBM autoantibody disease in 2022 and is expected to increase at a revenue CAGR of 4.3% by 2031.
Analysis of the global market for anti-GBM autoantibody disease indicates that during the forecast period, revenue share is likely to increase significantly. Anti-GBM disease is an autoimmune disorder that occurs when the immune system targets and kills healthy body tissue by mistake.
Key Takeaways:
- The increasing awareness of autoimmune disease is driving the market revenue share.
- The development of advanced diagnostic techniques for rapid disease diagnosis is driving the market demand.
- The use of monoclonal antibodies as therapy is increasing the market revenue growth rapidly.
Get a Free Sample Research Report: https://www.growthplusreports.com/inquiry/request-sample/antigbm-autoantibody-disease-market/8915
Anti-GBM Autoantibody Disease Market Scope
Report Attribute | Details |
CAGR | 4.3% |
Base Year for Estimation | 2022 |
Forecast Period | 2023 to 2031 |
Historical Year | 2021 |
Segments Covered | Treatment Type, Distribution Channel, and Region |
Regional Scope | North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa |
Recent Development in the Anti-GBM Autoantibody Disease Market:
- In February 2023, Imlifidase for Autoimmune Disorders is now in Phase III clinical research at Hansa Biopharma. A 63% phase transition success rate (PTSR) is the requirement for entering Pre-Registration for Phase III medications for autoimmune disorders.
Competitive Landscape
A list of the prominent players operating in the global market for anti-GBM autoantibody disease includes:
- Pfizer Inc.
- Bionic Medizintechnik GmbH
- Bristol-Myers Squibb Company
- Sun Pharmaceutical Industries Ltd.
- AbbVie, Inc.
- B. Braun Melsungen AG
Market Drivers and Restraints:
The global anti-GBM autoantibody disease market revenue is driven by the increasing…
[ad_2]